Physician

Mina Ayad Jacob, M.D.,FACC,FSCAI

According to 2025 Medicare claims, Mina Jacob, M.D., FACC, FSCAI (NPI: 1730132556) practices peripheral vascular disease in the Mobile, AL market, with the plurality of this provider's patient population coming from Mobile, AL. This provider's primary affiliated billing organization is IMC-DIAGNOSTIC AND MEDICAL CLINIC LLC (NPI: 1447201066; TIN: 631012832) and primary practice location at 36607-3513. Jacob is affiliated with the Ochsner Accountable Care Network, LLC (ACO ID: A1535), Piedmont Clinic ACO LLC (ACO ID: A3250), and Emory Healthcare Network Advantage (ACO ID: A4771), participating under the MSSP model.

Jacob's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 910 traditional Medicare patients, billed 5,443 HCPCS/CPT codes, and received $310,314 in Medicare payments. The top billing code was 99233 (Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes). Part D data shows 4,353 prescription claims across 767 beneficiaries totaling $694,539 in drug costs, led by Eliquis (Apixaban). Open Payments data shows 41 records totaling $3,732. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $166,012 to $310,314. Similarly, Part D prescription costs have moved sharply higher in recent years, from $57,696 to $694,539. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	840	2,103	$166,012
2016	1,115	2,862	$220,665
2017	933	2,321	$324,933
2018	866	3,008	$237,322
2019	1,110	4,652	$392,756
2020	1,163	4,522	$385,702
2021	1,151	4,481	$417,027
2022	1,156	4,773	$398,282
2023	1,062	4,895	$364,810
2024	910	5,443	$310,314

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	190	1,129	$57,696
2016	133	1,149	$71,442
2017	168	539	$35,005
2018	192	950	$66,200
2019	296	1,571	$164,079
2020	435	2,406	$290,869
2021	564	3,079	$363,288
2022	595	3,163	$385,620
2023	680	3,533	$525,926
2024	767	4,353	$694,539

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

No connected DME records

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99233	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes	152	563	$85
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	218	244	$78
93306	Ultrasound of heart with color-depicted blood flow, rate, direction and valve function	334	351	$76
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	297	442	$12
93010	Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only	198	271	$6

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Eliquis	Apixaban	366	16,698	$317,309
Entresto	Sacubitril/Valsartan	97	4,290	$95,116
Xarelto	Rivaroxaban	107	5,330	$93,610
Brilinta	Ticagrelor	43	1,805	$26,464
Repatha Sureclick	Evolocumab	28	1,120	$21,767

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	41	$3,732	Abbott Laboratories
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Mina Ayad Jacob, M.D., FACC, FSCAI?

Tedicare shows public-source Medicare data for Mina Ayad Jacob, M.D., FACC, FSCAI (NPI 1730132556), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Mina Ayad Jacob, M.D., FACC, FSCAI have ACO affiliation data?

Mina Ayad Jacob, M.D., FACC, FSCAI is shown with ACO affiliation data for Ochsner Accountable Care Network, LLC (MSSP, ACO ID A1535), Piedmont Clinic ACO LLC (MSSP, ACO ID A3250), and Emory Healthcare Network Advantage (MSSP, ACO ID A4771).

What billing organization is linked to Mina Ayad Jacob, M.D., FACC, FSCAI?

Mina Ayad Jacob, M.D., FACC, FSCAI is linked to IMC-DIAGNOSTIC AND MEDICAL CLINIC LLC (billing NPI 1447201066) in the available physician profile data.

Does Mina Ayad Jacob, M.D., FACC, FSCAI have Open Payments data?

Mina Ayad Jacob, M.D., FACC, FSCAI has 41 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.